Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: A randomised trial  by Sterling, Richard et al.
Respiratory Medicine (2012) 106, 1110e1115Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedEfficacy and optimal dosing interval
of the long-acting beta2 agonist, vilanterol,
in persistent asthma: A randomised trialRichard Sterling a,*, Jessica Lim b, Lucy Frith b, Neil G. Snowise b,
Loretta Jacques b, Brett Haumann baCarolina Research, Respiratory Medicine, Orangeburg, SC 29118-2040, USA
bRespiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge UB11 1BT, UK
Received 15 December 2011; accepted 12 March 2012
Available online 19 April 2012KEYWORDS
Vilanterol;
Persistent asthma;
Long-acting beta2
agonist;
Once-daily* Corresponding author. Tel.: þ1 80
E-mail address: sterlingent531@ya
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2012.03.007Summary
Background: Vilanterol (VI) is a novel once-daily long-acting beta2 agonist with inherent 24-h
activity. The aim of this study was to evaluate the efficacy of three once-daily doses and
one twice-daily dose of VI used concurrently with ICS in adult patients (18 years) with persis-
tent asthma. Safety was also assessed.
Methods: Multicentre, randomised, double-blind, placebo-controlled, five-period crossover
study consisting of 7-day treatment periods separated by 7-day wash-out periods. Seventy-
five patients, maintained on ICS, received VI 6.25, 12.5 and 25 mcg once-daily (evening), VI
6.25 mcg twice-daily (morning/evening), and placebo. The primary endpoint was trough forced
expiratory volume in 1 s (FEV1) (mean of 23 h and 24 h post evening dose) on Day 7; secondary
endpoint was weighted mean 24-h serial FEV1 on Day 7.
Results: All VI groups demonstrated statistically significant increases in trough FEV1 versus
placebo (p < 0.001). There was a statistically significant increase in weighted mean 24-h
FEV1 for each VI group versus placebo (p < 0.001). The effects of once-daily VI on trough
FEV1 and weighted mean 24-h FEV1 were dose dependent. The incidence of adverse events
(AEs) was low in each VI treatment group and was not dose dependent (5e9%;
placebo Z 18%); no drug-related AEs or serious AEs were reported.
Conclusion: Once-daily treatment with VI was well tolerated and associated with improve-
ments in lung function. The VI 6.25 mcg twice-daily dose showed the greatest change in trough
FEV1, however, similar changes in weighted mean 24-h FEV1 with VI 12.5 mcg once-daily were
observed. Although our study was not powered to demonstrate non-inferiority of once- versus
twice-daily dosing of VI, the data suggest no advantage over a 24-h period of twice-daily over
once-daily dosing for the same total daily dose.
ClinicalTrials.gov: NCT00980200.
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Vilanterol in persistent asthma 1111Introduction
chemistry assessments) physical exams and ECG; noInhaled corticosteroids (ICS) are recommended for patients
with asthma who are symptomatic on as-needed short-
acting beta2 agonist (SABA) (Step up from Step 1 to Step
2).1,2 Combination therapy consisting of an ICS and an
inhaled long-acting beta2 agonist (LABA) is recommended
for patients with persistent asthma who remain symptom-
atic despite ICS therapy (Step up from Step 2 to Step 3).1,2
Combination therapy in asthma is associated with increased
lung function and decreases in symptoms, exacerbation
frequency and need for rescue medication compared with
ICS alone.2e5 Current ICS/LABA combination therapies
(comprising the LABA salmeterol or formoterol) are
licensed for twice-daily use. Less complex dosing schedules
such as once-daily dosing may help to improve adherence to
asthma therapies as adherence to treatment can be prob-
lematic with long-term use.6,7 Poor adherence to therapy is
associated with poor asthma control.8,9 Vilanterol (VI;
GW642444M) is a once-daily LABA with inherent 24-h
activity in development in combination with the novel
ICS, fluticasone furoate (FF) for asthma and COPD. Once-
daily dosing with FF/vilanterol (VI) in a fixed-dose combi-
nation inhaler may increase treatment adherence by
providing greater convenience to the patient. The efficacy
and safety of VI dosed once-daily in the evening has been
demonstrated in patients with persistent asthma uncon-
trolled on ICS therapy.10 In this dose-ranging study, regular
once-daily treatment in the evening with VI was well
tolerated and resulted in prolonged bronchodilation of at
least 24 h at doses 12.5 mcg once-daily with the greatest
benefit seen at the 25 mcg dose.
The primary aim of the present phase IIb study was to
evaluate the efficacy of selected doses of VI (concurrently
with ICS) compared with placebo. The secondary aim was to
investigate the optimal dose interval (once-daily versus
twice-daily) of VI. Safety and tolerability of VI were also
assessed. The study was carried out in adult patients with
persistent asthma. Preliminary results have been presented
in the form of an abstract.11
Methods
Study subjects
At Visit 1 (screening) adult patients (18 years of age) were
eligible to enter the 7 (þ7 day) run-in period if they had
asthma according to the National Institutes of Health
criteria, forced expiratory volume in 1 s (FEV1) reversibility
of 12% and 200 mL following salbutamol/albuterol, and
had been taking ICS at a stable dose for 4 weeks prior to
screening and could replace their current SABA with albu-
terol/salbutamol for rescue use during the study. Details of
permitted and prohibited medications are provided in
Online Appendix 1. At the end of run-in, to be eligible for
randomisation, patients had to demonstrate either an
evening pre-dose percent predicted FEV1 between 40% and
<80%, or a FEV1 percent predicted of 80e85% and had
reported symptoms and/or used rescue salbutamol/albu-
terol on at least three of the last seven days of run-in.
Other criteria for randomisation included: normallaboratory test results (for haematological and clinical
reported asthma exacerbations during run-in and no change
in baseline asthma medication. Further information on
eligibility criteria at run-in and randomisation are provided
in Online Appendix 2.
All study participants gave written informed consent and
the study was approved by local ethics review committees
and conducted in accordance with the Declaration of Hel-
sinki and Good Clinical Practice guidelines.
Study design and treatments
This was a randomised, multicentre, double-blind, placebo-
controlled, five-period crossover study (HZA113310; www.
clinicaltrials.gov registration number NCT00980200) con-
ducted at nine centres in the USA between 15 September
2009 and 5 January 2010. Patients were randomly allocated
to one of five treatment sequences with each 7 (þ3) day
treatment period separated by a 7 (3/þ7) day wash-out
period; all patients received VI 6.25 mcg twice-daily, VI
6.25 mcg once-daily, VI 12.5 mcg once-daily, VI 25 mcg
once-daily and placebo. Patients were followed for 7 (3)
days at the end of the fifth treatment sequence or early
withdrawal. Treatments were administered via a new dry
powder inhaler. All patients and investigators were blinded
to treatment assignment, and the placebo and VI formula-
tions were indistinguishable. The central randomisation
schedule was generated by the sponsor using a validated
computerised system (RandAll). Patients were randomised
using Registration and Medication Ordering System
(RAMOS), an automated, interactive telephone based
system that was used by the investigator or designee to
register the patient, randomise the patient and receive
medication assignment information. Compliance was
assessed at the end of each 7-day treatment period by
reviewing the dose counter on the new dry powder inhaler.
Drug treatments and the inhaler device were manufactured
by GlaxoSmithKline, United Kingdom.
Outcome measurements
The primary efficacy endpoint was trough (pre-bronchodi-
lator and pre-dose) FEV1 at the end of the 7-day treatment
period (mean of 23-h and 24-h assessments post evening
dose). The secondary endpoint was the weighted mean for
24-h serial FEV1 (average area under the curve) on Day 7.
Serial 24-h FEV1 was measured on Day 7 of each of the five
treatment periods at: pre-dose, 30 and 60 min and 3, 5, 11,
12, 12.5, 13, 15, 17, 23 and 24 h post dose. Other endpoints
included the proportion of patients obtaining 200 mL and
12% increase from baseline in FEV1 (0e24 h) on Day 7.
Safety evaluation
Safety assessments included physical examination, labora-
tory assessments (haematological, biochemical and urinal-
ysis), ECG, vital signs and adverse events (AEs). Physical
examinations and laboratory assessments were made at
screening/run-in, at the end of the final (fifth) treatment
sequence and if the patient was withdrawn early from the
Figure 1 Patient disposition and reasons for discontinuation.
aIntent-to-treat population. bVI (6.25 mcg OD, 6.25 mcg BD,
12.5 mcg OD and 25 mcg OD) and placebo treatment. cOne
patient had PEF reading below stability limit and one patient
had FEV1 reading below stability limit. BD, twice-daily; FEV1,
forced expiratory volume in 1 s; OD, once-daily; PEF, peak
expiratory flow; and VI, vilanterol.
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vital signs were assessed at screening/run-in, during all five
treatment periods and if the patient was withdrawn early
from the study. AEs were also assessed at follow up. AEs
were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) dictionary. Patients were withdrawn
from the study due to lack of efficacy if they experienced
an asthma exacerbation (defined as worsening asthma
requiring treatment with oral/systemic steroids or emer-
gency department visit or in-patient hospitalisation for the
treatment of asthma).
Statistical analysis
To determine an appropriate sample size, the study was
powered to demonstrate superiority of each VI treatment
versus placebo for the primary endpoint. It was estimated
that approximately 75 patients were required to be rand-
omised to obtain 65 evaluable patients. This sample size
provided approximately 90% power to detect a 125 mL
treatment difference, assuming a within-patient standard
deviation of 210 mL, with a two-sided significance level of
5%. Additionally, a sample size of 65 ensured that the half-
width of the 95% confidence interval for the treatment
differences between any dose of VI and placebo was no
larger than approximately 75 mL.
The primary treatment comparisons were of each dose
regimen of VI versus placebo for trough FEV1 on Day 7.
Although comparisons of the once-daily and twice-daily
dosing regimens were of interest, the study was not pow-
ered to demonstrate non-inferiority of the once-daily
regimens relative to the twice-daily regimen. The primary
and secondary statistical analyses were performed using
a mixed effects analysis of covariance (ANCOVA) models
with fixed effects for treatment, period, sex and age.
Subject was fitted as a random effect and the period
baseline measurement (pre-dose FEV1 on Day 1) was
included as part of a bivariate response.
The intent-to-treat (ITT) population comprised all
randomised patients who received at least one dose of
study drug; all analyses of efficacy and safety measures
were performed in this population. The per-protocol (PP)
population comprised all patients in the ITT population not
identified as major protocol violators; this population was
used for confirmatory analyses of the primary efficacy
endpoint only. Further details of the analysis populations in
this study are provided in Online Appendix 3.
An exploratory efficacy analysis consisting of a repeated
measures analysis of change from period baseline in serial
FEV1 on Day 7 was performed; the model allowed for
effects due to the mean of the period baselines, period,
period baseline, treatment, sex, age, time (nominal) and
contained time-by-treatment and time-by-baseline inter-
action terms.
Results
Study population
Of 136 patients screened, 75 underwent randomisation (ITT
population) and 72 completed the study (Fig. 1). Therewere 74 patients in the PP population. Table 1 shows
baseline patient characteristics including ICS use and
screening lung function of the ITT population. Mean expo-
sure to study medication was 9.5e9.8 days and mean
overall compliance was >99%.Efficacy
All doses of VI were associated with statistically significant
increases in trough FEV1 on Day 7 versus placebo and the
differences from placebo with VI OD were dose-related (VI
6.25 mcg OD, 94 mL [95% CI: 49, 140 mL]; VI 12.5 mcg OD,
102 mL [95% CI: 57, 147 mL]; VI 25 mcg OD 125 mL [95% CI:
80, 170 mL]; VI 6.25 mcg BD 140 mL [95% CI: 95, 185 mL];
p < 0.001, all groups) (Fig. 2). Results in the per-protocol
population were consistent with those in the ITT pop-
ulation (data not shown).
All doses of VI were associated with statistically signifi-
cant increases in weighted mean 24-h serial FEV1 versus
placebo (p < 0.001) (Fig. 3). The effects with once-daily VI
were dose dependent (6.25 mcg, 153 mL; 12.5 mcg, 168 mL;
25 mcg, 185 mL); the response to VI 6.25 mcg twice-daily
was 166 mL.
A repeated measures analysis (difference from placebo
in change from period baseline in FEV1 with VI over 0e24 h
on Day 7) showed greater changes with VI 12.5 mcg once-
daily than 6.25 mcg twice-daily during the first 12 h but
the overall 24-h profiles were similar for the two dosing
regimens (Fig. 4a). There were also greater changes in lung
function with VI 25 mcg once-daily than with 6.25 mcg
twice-daily at 0e13 h and the changes were similar during
the 13e23-h period (Fig. 4b).
The proportion of patients who obtained a 200 mL and
12% increase from baseline FEV1 on Day 7 at any individual
timepoint was 19e38% across the VI groups and 12e22% for
placebo.
Table 1 Patient baseline demographics and screening
lung function (intent-to-treat population).
n Z 75
Age, years 38.9 (14.37)
Female, n (%) 47 (63)
Race, n (%)
White 51 (68)
African American/African heritage 23 (31)
Asian 1 (1)
Duration of asthma, n (%)
<6 months 0
6 months to <1 year 1 (1)
1 year to <5 years 3 (4)
5 years to <10 years 9 (12)
10 years 62 (83)
Screening lung function
Pre-bronchodilator FEV1 (L) 2.233 (0.7043)
Percent predicted FEV1 (%) 66.4 (10.37)
Percent reversibility in FEV1 (%) 27.9 (15.24)
ICSa use, n (%)
Fluticasone propionate 27 (36)
Budesonide 23 (31)
Mometasone furoate 15 (20)
Beclometasone dipropionate 8 (11)
Ciclesonide 2 (3)
Values are mean (SD) unless otherwise stated.
FEV1, forced expiratory volume in 1 s.
a Maximum allowable daily dose: fluticasone propionate
metered dose inhaler (MDI) 880 mcgb/1000 mcgc; fluticasone
propionate dry powder inhaler (DPI) 1000 mcg; budesonide
DPI/MDI 2000 mcg; mometasone furoate 880 mcg; beclo-
methasone dipropionate 1680 mcgb/2000 mcgc; ciclesonide
320 mcgb/400 mcg.c
b Zex-actuator dose.
c Zex-valve dose.
Figure 3 Weighted mean 24-h serial FEV1 (mL) on Day 7
(intent-to-treat population). BD, twice-daily; OD, once-daily;
and VI, vilanterol.
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VI was well tolerated at all doses and both dosing sched-
ules. The incidence of AEs was low in each VI treatment
group and not dose dependent (5e9%; placebo Z 18%)
(Table 2). The most common AE was nasopharyngitis, which
was reported by one patient each with 6.25 mcg once-daily
and 6.25 mcg twice-daily, by two patients with VI 12.5 mcg
once-daily, by one patient with 25 mcg once-daily and by no
patients with placebo. No AEs led to permanentFigure 2 Least squares mean change from baseline in trough
FEV1 (mL) on Day 7 (intent-to-treat population). BD, twice-
daily; OD, once-daily; and VI, vilanterol.discontinuation of study drug or withdrawal from the study
and no AEs were considered to be related to study treat-
ment. No pharmacologically predictable AEs were reported
(e.g. hypertension, extrasystoles or tremor). No serious AEs
or deaths were reported during the study.
The majority of patients did not have any reported clini-
cally relevant changes from pre-study baseline in vital signs.
Less than 20% of patients across the treatment groups had an
increase inpulse rateof>10beats/min, andwas generally no
greater with active treatment than with placebo. The
majority of patients (>80% across treatment groups) showed
a change from baseline of 15 to 15 mmHg in diastolic and
systolic blood pressure at pre-dose on Day 7.
Two patients reported an asthma exacerbation (one with
placebo and one with VI 12.5 mcg once-daily), both took
systemic/oral corticosteroids for their exacerbation but
neither patient withdrew from the study.
Discussion
The main objective of this study was to test the efficacy of
three once-daily doses (6.25, 12.5 and 25 mcg) and oneFigure 4 Repeated measures analysis of serial FEV1 (0e24-h)
comparing (a) 6.25 mcg BD with 12.5 mcg OD and (b) 6.25 mcg
BD with 25 mcg OD on Day 7 (intent-to-treat population).
Values are treatment differences (mL) from placebo. BD,
twice-daily; OD, once-daily; and VI, vilanterol.
Table 2 Summary of most commona on-treatment adverse events (intent-to-treat population).
Placebo
(n Z 74)
VI 6.25 mcg OD
(n Z 73)
VI 6.25 mcg BD
(n Z 74)
VI 12.5 mcg OD
(n Z 73)
VI 25 mcg OD
(n Z 73)
Any event, n (%) 13 (18) 5 (7) 7 (9) 4 (5) 6 (8)
Number of patients with most common event (%) 4 (5) 5 (7) 4 (5) 2 (3) 4 (5)
Nasopharyngitis 0 1 (1) 1 (1) 2 (3) 1 (1)
Upper respiratory tract infection 1 (1) 0 3 (4) 0 0
Road traffic accident 0 0 0 0 3 (4)
Back pain 2 (3) 0 0 0 0
Headache 1 (1) 2 (3) 1 (1) 0 0
Rhinitis perennial 0 2 (3) 0 0 0
BD, twice-daily; OD, once-daily; and VI, vilanterol.
a Most common is defined as 3% in any treatment group.
1114 R. Sterling et al.twice-daily dose (6.25 mcg) of VI for 7 days in adult patients
with persistent asthma receiving maintenance ICS. Safety
and tolerability of VI were also assessed. VI dosed once-
daily or twice-daily was associated with significant
increases from baseline trough FEV1 versus placebo
(primary endpoint), with the greatest numerical improve-
ment reported with VI 6.25 mcg twice-daily. Significant
improvements in weighted mean 24-h serial FEV1 (versus
placebo) were also observed with both once-daily and
twice-daily VI. The effects of once-daily VI on lung function
were dose-related with the greatest numerical increases at
25 mcg for both trough FEV1 and weighted mean serial 24-h
FEV1 relative to baseline.
Our study was a confirmatory study to the larger
B2C109575 study (n Z 614 patients randomised).10
B2C109575 was a 28-day, placebo-controlled, dose-ranging
study that investigated the efficacy and safety of five VI
doses (3, 6.25, 12.5, 25 and 50 mcg) administered once-
daily in the evening in patients with persistent asthma
and receiving maintenance ICS. Preliminary results showed
that although VI 12.5 mcg had a favourable therapeutic
ratio, the greatest benefit was seen with VI 25 mcg once-
daily.10 The information provided from the B2C109575 study
formed the basis of the VI doses and treatment periods
selected in the present study. Although our study was not
a definitive dose-ranging study, the significant improve-
ments with once-daily VI at 12.5 and 25 mcg provide addi-
tional support to the previously observed efficacy and
tolerability of VI at these doses.10 Although results cannot
be directly compared between our study and the
B2C109575 study due to differences in trial design, duration
and study population, the magnitude of improvements
reported for once-daily VI at 6.25, 12.5 and 25 mcg on
trough FEV1 and weighted mean 24-h serial FEV1 were
similar.
A further objective of our study was to compare the
efficacy of VI dosed once-daily versus twice-daily. Although
our study was not powered to directly compare once-daily
with twice-daily dosing, results for weighted mean serial 24-
h FEV1 support once-daily dosing of VI. The VI 12.5mcg once-
daily dose was associated with a similar magnitude of bron-
chodilation at Day 7 as VI 6.25 mcg twice-daily, indicating
similar improvements regardless of whether the same total
daily dose was given once-daily or twice-daily (Fig. 3).
Weighted mean serial 24-h FEV1 may be a more relevant
endpoint than trough FEV1 to demonstrate the 24-h activityof a therapy, but the results seen with once-daily VI on both
these endpoints support the 24-h duration of effect of VI.
Currently licensed ICS/LABA combination therapies
(such as fluticasone propionate/salmeterol and budeso-
nide/formoterol) for asthma are dosed twice-daily due to
their duration of action. In a study that compared (versus
placebo) the duration of bronchodilation following a single
dose of fluticasone propionate/salmeterol or budesonide/
formoterol, sustained bronchodilation over 24 h was
observed for both drug combinations, however, the authors
hypothesised that this may not be clinically significant as
lung function values had approached baseline values by
24 h.12 In contrast, in our study, sustained clinically rele-
vant bronchodilation was observed over 24 h versus placebo
with both VI dose regimens and all VI doses. Furthermore,
a greater proportion of patients obtained a 200 mL and
12% improvement in baseline FEV1 across the VI treatment
groups compared with placebo.
VI was well tolerated at all doses and both dose regi-
mens. The incidence of AEs was low and similar across the
active treatment groups with the highest incidence of AEs
reported in the placebo group. No AEs commonly associated
with LABA use were reported (eg. tremor, hypertension,
extrasystoles). Nasopharyngitis was the AE most commonly
reported with VI but was not dose-related. Three road
traffic accidents were reported as AEs by three patients in
the VI 25 mcg dose group but none were considered treat-
ment related. The investigators confirmed that the
circumstances of the accidents were not suggestive of
there being any association of a drug-related effect. Two
patients reported an asthma exacerbation on the last day of
their final (fifth) treatment sequence and received corti-
costeroids for their exacerbation but were not withdrawn
from the study. No serious AEs, hospitalisations or deaths
were reported in our study. The overall favourable safety
profile of VI in this short-term study supports that reported
for the same once-daily doses of VI investigated in the 28-
day B2C109575 study.10 The long-term safety and tolera-
bility of VI clearly needs to be assessed in future trials.
Our study has important strengths, including the cross-
over design which meant patients acted as their own
‘controls’ and the high overall rate of compliance across
the treatment groups (>99%). A limitation of the study was
that the primary endpoint was change in trough FEV1
relative to placebo. Although this endpoint is sufficiently
sensitive to show the dose responsiveness of a treatment,
Vilanterol in persistent asthma 1115weighted mean 24-h serial FEV1 represents a measure more
suited to assessing the relative effects of once-daily and
twice-daily dosing. Furthermore, weighted mean FEV1
considers changes (above baseline) in bronchodilation over
a 24-h period and can therefore provide a better assess-
ment (versus trough FEV1) on whether there is an efficacy
advantage when VI is dosed twice-daily versus once-daily. A
further limitation of our study was that it was not formally
powered for non-inferiority of once-daily versus twice-daily
dosing of VI. Rather, the relative effects of the different
dose intervals were compared by assessing the overlap in
point estimates and 95% CI for placebo-adjusted improve-
ments from baseline. In addition, the study was of a short
duration but was designed to substantiate the findings of
B2C109575 and to provide information on once-daily versus
twice-daily dosing.
In summary, once-daily administration of VI (6.25e25mcg)
over 7 days in patients with asthma maintained on ICS was
associated with significant improvements in lung function
relative to placebo, with maximal improvements in lung
function over 24 h observed with VI 25 mcg once-daily. The
similar improvements in weighted mean 24-h serial FEV1 with
12.5 mcg once-daily and 6.25 mcg twice-daily suggests no
advantage over a 24-h period of twice-daily versus once-daily
dosing for the same total daily dose. Once-daily treatment
with VI was well tolerated with no safety signals. The findings
support the further development of VI as part of a once-daily
fixed combination therapy with an ICS for the treatment of
asthma.
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